Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 239

Study of BDC-1001 and Pertuzumab for Patients with HER2-Positive Metastatic Breast Cancer Previously Treated with Trastuzumab Deruxtecan

Study of BDC-1001 and Pertuzumab for Patients with HER2-Positive Metastatic Breast Cancer Previously Treated with Trastuzumab Deruxtecan

Study on the Effectiveness and Safety of Idecabtagene Vicleucel for Patients with Relapsed or Refractory Multiple Myeloma

Study on the Effectiveness and Safety of Idecabtagene Vicleucel for Patients with Relapsed or Refractory Multiple Myeloma

Study on IO102-IO103 and Pembrolizumab for Patients with Metastatic Lung, Head and Neck, or Bladder Cancer

Study on IO102-IO103 and Pembrolizumab for Patients with Metastatic Lung, Head and Neck, or Bladder Cancer

Study on the Effectiveness and Safety of Erdafitinib, Midazolam, and Metformin in Patients with Advanced Urothelial Cancer

Study on the Effectiveness and Safety of Erdafitinib, Midazolam, and Metformin in Patients with Advanced Urothelial Cancer

Study of Tisotumab Vedotin, Pembrolizumab, and Platinum Drug Combination for Patients with Advanced or Metastatic Solid Tumors

Study of Tisotumab Vedotin, Pembrolizumab, and Platinum Drug Combination for Patients with Advanced or Metastatic Solid Tumors

Study of Niraparib and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Study of Niraparib and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Study on Durvalumab and Platinum-Based Drug Combination for Patients with Stage IIB-IIIB Non-Small Cell Lung Cancer

Study on Durvalumab and Platinum-Based Drug Combination for Patients with Stage IIB-IIIB Non-Small Cell Lung Cancer

Study of Elranatamab, Dexamethasone, and Diphenhydramine Hydrochloride for Patients with High-Risk Smoldering Multiple Myeloma

Study of Elranatamab, Dexamethasone, and Diphenhydramine Hydrochloride for Patients with High-Risk Smoldering Multiple Myeloma

Study on Alectinib and Durvalumab for Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer

Study on Alectinib and Durvalumab for Patients with Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer

Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

Study on Luspatercept for Patients with Lower-risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

Study on Durvalumab with Oleclumab or Monalizumab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy

Study on Durvalumab with Oleclumab or Monalizumab for Patients with Stage III Unresectable Non-Small Cell Lung Cancer After Chemoradiation Therapy